Kayla Hartjes

Dr. Kayla Hartjes

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
TSTracey G. Simon
Tracey G. Simon
BRBjorn Roelstraete
Bjorn Roelstraete
KHKayla Hartjes
Kayla Hartjes
USUzma Shah
Uzma Shah
HKHamed Khalili
Hamed Khalili
JLJonas F. Ludvigsson
Jonas F. Ludvigsson

29 December 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
NKNanda Kerkar
Nanda Kerkar
KHKayla Hartjes
Kayla Hartjes
Hepatitis C virus (HCV) infects both pediatric and adult populations and is an important cause of chronic liver disease worldwide. There are differences in the screening and management of HCV between pediatric and adult patients, which have been highlighted in this review. Direct-acting antiviral agents (DAA) have made the cure of HCV possible, and fortunately, these medications are approved down to three years of age. However, treatment in the pediatric population has its own set of challenges. The World Health Organization (WHO) has made a pledge to eliminate HCV as a public health threat by 2030. Despite this, HCV continues to remain a global health burden, leading to cirrhosis as well as hepatocellular carcinoma, and is a reason for liver transplantation in the adult population. Although rare, these complications can also affect the pediatric population. A variety of new technologies t have become available in the current era and can advance our understanding of HCV are discussed. Artificial intelligence, machine learning, liver organoids, and liver-on-chip are some examples of techniques that have the potential to contribute to our understanding of the disease and treatment process in HCV. Despite efforts over several decades, a successful vaccine against HCV has yet to be developed. This would be an important tool to help in worldwide efforts to eliminate the virus.

19 February 2026 in Hepatology Communications
Verified
Journal Article
Open access
SWSharad I. Wadhwani
Sharad I. Wadhwani
PSPooja Reddy Spector
Pooja Reddy Spector
AFAmy G. Feldman
Amy G. Feldman
KFKatryn N. Furuya
Katryn N. Furuya
KHKayla Hartjes
Kayla Hartjes
PVPamela L. Valentino
Pamela L. Valentino
Background: Despite major advances in surgical and medical management, only one-third of pediatric liver transplant (LT) recipients remain morbidity-free at 10 years. The Society of Pediatric Liver Transplantation (SPLIT) published a research agenda over 10 years ago, and much progress has been made since then. An updated consensus-driven SPLIT research agenda could guide future research and funding priorities. We aimed to identify and prioritize key research needs across the continuum of pediatric LT care using a modified Delphi consensus approach. Methods: We conducted a three-round modified Delphi process among SPLIT members. In round 1, participants submitted open-ended research priorities. In round 2, the Steering Committee synthesized these into 156 unique statements for rating. The third and final round included revision and rerating of 42 statements. Consensus was defined as a median importance rating ≥7 on a 9-point Likert scale. Results: Sixty-nine multidisciplinary experts participated in round 1, with <30% attrition across rounds. The panel identified 46 high-priority research topics, organized into 7 domains: (1) end-stage disease and waitlist management; (2) transplant access, allocation, and organ utilization; (3) perioperative management; (4) immunosuppression management; (5) transplant complications; (6) long-term health and transition to adulthood; and (7) special populations. Highest-ranked research priorities included (1) developing an updated LT waitlist allocation scoring tool, (2) identifying novel biomarkers to guide immunosuppression minimization/withdrawal, and (3) developing new organ preservation strategies to increase the availability of high-quality organs for pediatric LT candidates. Conclusions: SPLIT members identified 46 consensus research priorities that define the next frontier of pediatric LT research and provide a roadmap for investigators, funders, and health systems to improve survival and lifelong health in children after LT. Export